Conversely, administration of NOS/NMDA-R activators (L-arg and NMDA) worsened the negative effects of MS on behavior and increased nitrite levels and the expression of iNOS, nNOS, NR2A, and NR2B genes in the hippocampus. The gene discussed is GRIN2A; the disease is myeloid sarcoma.